About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT01581138

VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

The purpose of this study is to evaluate the efficacy and safety of two all oral regimens in subjects who have chronic hepatitis C and have not received treatment yet.

Lead sponsor: Vertex Pharmaceuticals Incorporated•18 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Vertex Pharmaceuticals Incorporated

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Subjects must have genotype 1 chronic hepatitis C (CHC) and laboratory evidence of HCV infection for at least 6 months before the Screening Visit
•Subjects will be treatment naïve
•Subjects must have documentation of the presence or absence of cirrhosis

Exclusion Criteria

•History or other clinical evidence of significant or unstable cardiac disease
•Evidence of hepatic decompensation
•Diagnosed or suspected hepatocellular carcinoma
•Any other cause of significant liver disease in addition to hepatitis C, which may include but is not limited to malignancy with hepatic involvement, hepatitis B, drug-or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, nonalcoholic steatohepatitis, or primary biliary cirrhosis
•History of organ transplant, with the exception of corneal transplants and skin grafts

Related studies

COMPLETEDPhase 3

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

NCT02219490 · Chronic Hepatitis C Virus (HCV) Infection Genotype 1

COMPLETEDPhase 3

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

NCT02167945 · Chronic Hepatitis C Virus (HCV) Infection Genotype 1

COMPLETEDPhase 3

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection

NCT02640482 · Chronic Hepatitis C Virus (HCV) Infection

COMPLETEDPhase 3

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection

NCT02707952 · Chronic Hepatitis C Virus, Hepatitis C Virus

COMPLETEDPhase 1/2

Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients

NCT04391985 · Chronic Hepatitis C Virus Infection

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 4, 2014Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment64

Start dateJul 2012

Last updatedJul 4, 2014

Condition

Chronic Hepatitis C Virus

Locations shown

Birmingham, Alabama

Anaheim, California

Riverside, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 4, 2014Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions